Increased dosage of methyl-CpG-binding protein-2 (MeCP2) results in a dramatic neurodevelopmental phenotype with onset at birth. We generated induced pluripotent stem cells (iPSCs) from patients with the MECP2 duplication syndrome (MECP2dup), carrying different duplication sizes, to study the impact of increased MeCP2 dosage in human neurons. We show that cortical neurons derived from these different MECP2dup iPSC lines have increased synaptogenesis and dendritic complexity. In addition, using multi-electrodes arrays, we show that neuronal network synchronization was altered in MECP2dup-derived neurons. Given MeCP2 functions at the epigenetic level, we tested whether these alterations were reversible using a library of compounds with defined activity on epigenetic pathways. One histone deacetylase inhibitor, NCH-51, was validated as a potential clinical candidate. Interestingly, this compound has never been considered before as a therapeutic alternative for neurological disorders. Our model recapitulates early stages of the human MECP2 duplication syndrome and represents a promising cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.
INTRODUCTION
We previously showed that increased dosage of methyl-CpGbinding protein-2 (MeCP2) leads to a severe neurodevelopmental disorder in males, designated as the MECP2 duplication syndrome (MECP2dup) (MIM 300260). 1, 2 The increased dosage of MeCP2 is the result of a copy number gain at Xq28, including the MECP2 gene, and results in severe to profound neurodevelopmental delay with onset at birth, limited or absent speech, hypotonia, epilepsy, autistic behavior and motor dysfunction. [1] [2] [3] [4] [5] Several studies in transgenic mice, overexpressing MECP2, have shown a progressive neurological phenotype, including tremor, gait ataxia, seizures, anxiety, abnormal learning and behavior, and early death, recapitulating some aspects of the human disease. [6] [7] [8] [9] The MeCP2 protein is widely expressed in various human tissues, but its increasing expression in the postnatal neural lineage suggests a key role in neurodevelopment, including the maturation, dendritic arborization and axonal outgrowth of the central nervous system. 10, 11 Loss-of-function mutations in MECP2 cause Rett syndrome (RTT) (MIM 312750) as well as other neurobehavioral disorders, indicating that MECP2 gene dosage is critical for human neurodevelopment. 12 Human induced pluripotent stem cells (iPSCs) constitute a promising tool for investigating the underlying pathophysiology of traditionally challenging neurodevelopmental disorders. 13 We have demonstrated the utility of iPSCs to investigate the functional consequences of MECP2 loss of function. 14, 15 Neurons generated from RTT patients' iPSCs exhibited several alterations, including decreased soma size, altered dendritic spine density and reduced excitatory synapses. Therefore, functional studies using iPSC-derived neuronal cultures from patients carrying MECP2 mutations can help delineate the mechanism by which alterations in MeCP2 dosage lead to disease and, ultimately, serve as a screening system to test potential therapeutic compounds. In this study, we present the development and analysis of a human iPSC model for the MECP2 duplication syndrome. In addition, we screened an epigenetic chemical library and found one compound able to successfully reverse several aspects of the observed neuronal phenotype.
Patient ascertainment
Fibroblasts were obtained from three independent patients diagnosed with MECP2 duplication syndrome as follows:
Patient 1 (male) was born after an uneventful pregnancy as the first child to healthy non-consanguineous parents. At birth, he was very hypotonic with feeding problems. His development was severely delayed, with sitting at the age of 2 years and walking with support at the age of 3.5 years. He did not develop any active speech and shows repetitive behavior and hand flapping when he is excited. He suffered from recurrent infections occurring since the first months of life, necessitating almost continuous antibiotic therapy and frequent hospitalizations. At the age of 6 years, he was ventilated for 1 week because of a serious pneumonia. After this period, he lost ambulation and his epilepsy got worse. Array comparative genome hybridization (array-CGH) at the age of 2 years showed a very small duplication of 300 kb at Xq28 (152.73-153.02 Mb). Within this interval, MECP2 is the only known brain-expressed gene involved in a human disorder (Figure 1a ).
Patient 2 (male) was born from non-consanguineous parents with negative family history. He showed severe hypotonia at birth and was
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MECP2dup control (Figure 1a) . Patient 3 (male) was born at term as the first child of healthy non-consanguineous parents. His family history is significant for three maternal uncles and a maternal cousin who died in the second or third decades of life with a similar clinical picture. The patient had developmental delays from birth. He had severe gastroesophageal reflux and was difficult to soothe as an infant. He sat up at 1 year, did not crawl and did not walk until 2.5 years. He exhibited language delays from birth and learned some basic communication skills using a Picture Exchange Communication System (PECS) board or basic signs. Hand and mouth stereotypies were frequent. He was formally diagnosed with autism at age 7 years. Medically, he experienced constipation, drooling, bruxism and recurrent respiratory infections. At age 8 years, he developed medically refractory epilepsy and experienced developmental regression. He lost the ability to ambulate and became wheelchair dependent. He lost use of his hands and the limited interactive skills that he had gained. Severe dysphagia developed and a gastrostomy tube was placed, which is his sole source of nutrition. Seizures persist despite placement of a vagus nerve stimulator and use of the ketogenic diet. Pneumonias became frequent despite the use of prophylactic antibiotics and necessitated hospitalization and ventilatory support on numerous occasions. Array-CGH revealed that the patient has duplication of 500 kb at Xq28 (152.66-153.15 Mb) that includes MECP2 (Figure 1a ). Patient 3 was previously described in Carvalho et al. 16 (as patient BAB2623).
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Cell culture
Inactivated mouse embryonic fibroblasts (GlobalStem, Rockville, MD, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) HG (Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA). Skin fibroblasts obtained from explants of dermal biopsy of male patients with MECP2 duplication syndrome and BJ1 fibroblast cells were maintained in DMEM F-12 (Life Technologies) containing 10% fetal bovine serum. iPSC clones were normally expanded on inactivated mouse embryonic fibroblast feeders using human embryonic stem cell medium comprising DMEM-F12, 10% KSR (both from Life Technologies), 200 mM L-glutamine, β-mercaptoethanol (both from Sigma-Aldrich) and basic fibroblast growth factor (bFGF; Life Technologies) and passaged by using collagenase. For feeder-free culturing, cells were grown on matrigel-coated dishes (BD Biosciences, San Jose, CA, USA) and mTeSR1 from StemCell Technologies (Vancouver, BC, Canada) and passaged by using dispase.
Generation of iPSCs
Skin fibroblasts derived from patients with MECP2 duplication syndrome were infected with pMXs retroviral vectors containing coding sequences of human OCT4, SOX2, KLF4 and C-MYC (obtained from Addgene, Cambridge, MA, USA). 18 Four days post infection, fibroblasts were trypsinized to singles and plated on the inactivated mouse embryonic fibroblast feeders, and cultured using human embryonic stem cell medium. After 3-4 weeks, iPSC clones were manually picked and were further propagated clonally on feeders. Control 1 was derived from normal, healthy male donor fibroblasts (kind gift of Professor Nadif-Kasri N, Nijmegen, The Netherlands). Control 2 was also generated from healthy male donor fibroblasts (Muotri Lab, UCSD). The Control 3 iPSC clone was derived from BJ1 fibroblasts (Verfaillie Lab, KU Leuven).
RNA extraction and qRT-PCR
Total RNA was extracted using RNeasy Micro Kit from Qiagen (Valencia, CA, USA). cDNA was synthesized by taking 1 μg of total RNA and superscript III first-strand kit (Life Technologies) as per the manufacturer's instruction. Quantitative reverse-transcriptase PCR (qRT-PCR) was performed using gene-specific primers (primer sequences available on request) and SYBR Green Platinum SuperMix from (Life Technologies). The expression of target genes and the endogenous control were measured with technical duplicates in each qRT-PCR reaction. To obtain statistical significance, values from a minimum of three independent differentiation qRT-PCR runs were considered. GAPDH was used as the endogenous control. The cycle threshold number (C t ) was calculated using RQ Manager 1.2 Software (Life Technologies). The relative expressions of each target gene across differentiation days were normalized using 2 (− ΔΔCt) method compared with differentiation day 5. Similarly, the fold expression of genes in the patient differentiation samples were calculated using 2 ( − ΔΔCt) method compared with differentiation day 5 of control cells.
Immunocytochemistry
Cells grown on coverslips were fixed using 4% paraformaldehyde (PFA) for 20 min at room temperature (RT). Cells were permeabilized and blocked using a buffer containing 5% horse/donkey/goat serum, 3% bovine serum albumin and 0.3% Triton X-100 for 30 min at RT. Primary antibodies diluted in antibody diluent (1% horse/donkey/goat serum+3% bovine serum albumin+0.1% Triton X-100) were incubated overnight at 4°C. Secondary antibodies were incubated for 1 h at RT. Cells were washed three times with phosphate-buffered saline (PBS)+0.1% Tween-20. Hoechst (4 μg ml −1 ) was used to visualize nuclei. Coverslips were mounted on slides using Prolong Gold mounting medium (Life Technologies). Images were acquired using confocal microscope Radiance 2100 (Zeiss, Oberkochen, Germany) equipped with an upright microscope (Eclipse E800; Nikon, Tokyo, Japan). The Supplementary Table S5 provides a detailed description of the antibodies used in this study.
Teratoma formation
Fully grown iPSCs on feeders were dissociated by using collagenase for 3-4 min at 37°C. Cells re-suspended in PBS and matrigel (1:1) were injected subcutaneously into dorsal flanks of immune-compromised Rag2 − / − GammaC − / − mice. Five to six weeks later, teratomas were excised and fixed by using 4% PFA at 4°C for overnight. Fixed tumor was embedded in paraffin and sections of 5 μm thickness were made using microtome for histological studies. The tissue sections were stained with hematoxylin and eosin and analyzed for the presence of the different germ layer tissues.
EB formation
Feeder-free cultured iPSCs were dissociated using dispase for 5 min at 37°C and centrifuged for 3 min at 1200 r.p.m. Cell pellet was re-suspended in embryoid body (EB) medium (IMDM medium, 15% fetal bovine serum, 2 mM L-glutamine, 1% non-essential amino acids, 1 mM sodium pyruvate, 100 U penicillin/streptomycin, 200 μg ml − 1 iron-saturated transferrin, 10 μM β-mercaptoethanol, 50 μg ml − 1 ascorbic acid (Sigma-Aldrich)) supplemented with ROCK inhibitor and plated on 'low attachment plate'. Medium was changed every alternate day by centrifuging at 700 r.p.m. for 1 min and re-suspending gently using fresh medium. After 8 days, EBs were re-plated on a plate pre-coated with gelatin for 30 min at RT. The attached cells were maintained for 8 more days in EB medium and were taken for gene expression analysis.
Protein isolation and immunoblotting
Cells were collected and lysed in a buffer containing 50 mM Tris-HCl at pH 7.4, 300 mM NaCl, 1 mM dithiothreitol, 0.5% Triton X-100 and protease inhibitors, and sonicated briefly. Total cell lysates were centrifuged at 6000 r.p.m. for 10 min at 4°C. Protein concentration was measured using Bradford's reagent. Subsequently, 30 μg of proteins were loaded on NuPAGE, 10% Bis-Tris Gel using morpholino-propane sulphonic acid (MOPS) buffer at 200 V for 1 h and then transferred to polyvinylidene fluoride membrane using Life Technologies' iBlot system. Further, membrane blocking was performed using Tris-buffered saline (TBS) with 5% milk powder and 0.1% Tween-20 for 45 min at RT. The membrane was incubated with primary antibody, mouse anti-MeCP2 (1:1000; Sigma-Aldrich) diluted in blocking buffer for overnight at 4°C. Horseradish peroxidase-conjugated anti-mouse antibody was used as secondary and incubated for 1 h at RT. Rabbit anti-GAPDH was used as a loading control. Proteins were detected using Western Blot Chemiluminescence reagent Plus kit (Perkin-Elmer, Waltham, MA, USA) as per manufacturer's instruction.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was performed using the ChIP-IT Express Enzymatic kit (Active Motif, Carlsbad, CA, USA). Briefly, starting with 10-cm plates, cross-link was induced in cells with 1% formaldehyde for 10 min at RT. After washout with ice-cold PBS, the reaction was stopped with Glycine Stop-Fix Solution (Active Motif) for A human MECP2 duplication model S Nageshappa et al 5 min and plates were washed again with PBS. Cells were then suspended in Cell Scraping Solution (Active Motif) and pelleted by centrifugation (720 g for 10 min at 4°C). The cell pellet was re-suspended in 1 ml of icecold lysis buffer, Dounce homogenized with 15 strokes and centrifuged for 10 min at 2400 g and 4°C. The nuclei pellet was re-suspended in 350 μl of Digestion Buffer. After 5 min incubation at 37°C, the solution was supplemented with 17 μl of Enzymatic Shearing Cocktail (200 U ml − 1 ) and incubated for more 15 min at 37°C. The ChIP reaction was set up with 25 μg of sheared chromatin, 2 μg of anti-MeCP2 antibody (Diagenode, Denville, NJ, USA) and Protein G Magnetic Beads. The reaction was incubated on an end-to-end rotator for 16 h at 4°C. A magnetic stand was used collect the magnetic beads at the end of incubation and subsequent washes (once with ChIP Buffer 1 and twice with ChIP Buffer 2). Washed beads were re-suspended in 50 μl of Elution Buffer AM2 and incubated at RT under agitation for 15 min. Cross-link was reverted with 50 μl of reverse cross-linking buffer, removal of supernatant after pelleting the beads with the magnetic stand and incubation of the solution at 95°C for 15 min. Finally, the supernatant was incubated at 37°C for 1 h with proteinase K followed by addition of 2 μl of Proteinase K Stop Solution (Active Motif). The DNA was immediately used on end-point PCR and quantitative PCR reactions (primer sequences available on request). The antibody conditions for the ChIP assay were validated with brain-derived neurotrophic factor promoter in exon IV and another region (negative) of the promoter as previously described. 19 Copy number variation analysis by array-CGH Genomic DNA isolated from patient and control iPSCs using PureLink Genomic DNA Mini Kit (Life Technologies) was subjected to copy number variation analysis on 180 k Cytosure ISCA v2 arrays (Oxford Gene Technology, Begbroke, Oxfordshire, UK). Arrays were designed to be used in two-color experiments, that is, one sample was labeled with fluorescent dye Cy3 and another sample was labeled with fluorescent dye Cy5. Array-CGH was performed according to the manufacturer's recommendations. Dye swap design was used for DNA labeling, and post hybridization and washing the slide was scanned with an Agilent G2565CA Microarray Scanner (Agilent Technologies, Santa Clara, CA, USA). Raw data were generated using the accompanied Feature Extraction software (Agilent Technologies). Data were analyzed by means of the CytoSure Interpret software v.10 (Oxford Gene Technology).
Differentiation of human iPSCs into neurons with a cortical fate
Differentiation was done as previously described. 20 iPSCs were dissociated into single cells by using accutase (Sigma-Aldrich) and were plated on Matrigel (human embryonic stem cell-qualified matrigel; BD)-coated plates/coverslips using mTeSR medium supplemented with 10 μM ROCK inhibitor (Calbiochem, Spring Valley, CA, USA). This day was designated as 'day-2'. Post 48 h, that is, on 'day 0', medium was changed to chemically defined default medium supplemented with B-27 (Life Technologies; 10 ml per 500 ml of medium) and the differentiation was induced by adding 100 ng ml − 1 of Noggin (R&D Systems, Minneapolis, MN, USA) for 16 days with alternate days of medium change. After the 16th day, cells were cultured by using defined default medium supplemented with B-27 but without Noggin until day 24. Neural progenitor cells (NPCs) were mechanically dissociated and plated (using defined default medium with B-27 medium) at a density of 50 000 cells per well of a 12-well plate having coverslips (18 mm) with poly-lysine and Laminin (both from BD Biosciences). ROCK inhibitor (10 μM) was added to aid survival. Approximately a week later, half of the medium was replaced with Neurobasal medium (Life Technologies) supplemented with B-27 (10 ml B-27 over 500 ml medium) along with L-glutamine (2 mM). This procedure was repeated every 5-7 days.
Sholl analysis
Cells differentiated on coverslips were fixed at day 40 of differentiation using 4% PFA and immunostained with antibody against anti-MAP2. NIH ImageJ software (Bethesda, MD, USA) with built-in 'Sholl analysis' option was used to quantify neuritic complexity. Analysis was done by specifying a center point at the middle of each soma and by placing a grid with concentric rings of radii increasing in increments of 10 μm and the number of intersections was used to estimate the total dendritic branch.
Neuronal connectivity
Wheat germ agglutinin (WGA) was used as a trans-synaptic tracer to verify neuronal connectivity. 21, 22 Three-week-old neurons were transfected with 1 μg of MSCV-AcGFP-P2A-WGA construct 1 using Lipofectamine 3000 reagent (Life Technologies) according to the manufacturer's instructions. Seven days after transfection, neurons were fixed with 4% PFA and immunocytochemistry performed. The primary antibodies were mouse anti-green fluorescent protein (GFP; 1:1000; Millipore, Billerica, MA, USA) and rabbit anti-WGA (1:5000; Sigma-Aldrich) antibodies.
Synaptic puncta quantification
Quantification of co-localized pre-and post-synaptic puncta was performed after immunostaining with Vglut-1 and PSD95 as previously described. The primary antibodies (PSD95, 1:1000, NeuroMab, Davis, CA, USA; Vglut-1, 1:1000, Synaptic Systems, Goettingen, Germany; and MAP-2, 1:2000, Sigma-Aldrich) were incubated for 2 h. After post treatment with secondary antibodies and incubation for 1 h, coverslips were mounted and slides were analyzed under a fluorescence microscope (Z1 Axio Observer Apotome, Zeiss). Only Vglut1 and PSD95 puncta along MAP-2-positive processes were counted. Lentivirus overexpression and knockdown of MECP2 were performed as described previously.
14 Spine density and morphology pHIV7/Syn-EGFP lentivirus was prepared by transfecting HEK cells using the transfection agent polyethylenimine (Polysciences, Inc., Warrington, PA, USA), pSyn-EGFP and packaging plasmids pMDL, Rev RSV and VSVG. During cortical neuron differentiation, on day 40, control and MECP2dup neurons were transduced with pHIV7/syn-EGFP. Post transduction, neurons were further differentiated until day 70 and were fixed with 4% PFA and further processed for imaging. Confocal images were obtained using a confocal laser-scanning microscope (Nikon), × 60 oil objective, with a sequential acquisition setting at 4096 × 4096 pixels resolution. Each image is a Z-series projection of~7 to 15 images, averaged 2 times and taken at 0.5 μm depth intervals. GFP-labeled differentiated neurons were chosen randomly for quantification. Quantitative analysis was performed in a blinded manner. Dendrites on primary branches were selected randomly and for each neuron two to three segments of 10 μm were analyzed. Morphometric measurements were performed manually using the ImageJ software (1.44p version). Each spine on the dendrites was manually traced. The length and head width of each spine was automatically measured and used to categorize the spines. 23 Specifically, spines where defined as thin and filopodia (immature) or mushroom and stubby (mature) according to the criteria defined previously. 23 Twenty-two (51 segments of 10 μm) and 18 (42 segments of 10 μm) neurons were analyzed for the control and MECP2dup neurons, respectively; two clones for each condition.
Multi-electrode array assays
To generate functional neural networks, growing NPCs were dissociated with Accutase and placed on six-well dishes (10 6 cells per well) under shaker agitation (95 r.p.m.) at 37°C. The media used was DMEM-F12 supplemented with 0.5 × B-27, 0.5 × N2 and 20 ng ml − 1 of bFGF (all from Life Technologies). The next day (day 0), neural fate was induced by removing bFGF and adding 10 μM Rock inhibitor Y-27632 (Tocris, Minneapolis, MN, USA). Two days later (day 2), media was changed to fresh media without Rock inhibitor. The differentiation took place for 2 weeks in suspension, with media change every 4 days. On day 15 of differentiation, these 3D neurosphere cultures were plated on multielectrode array (MEA) assay probes containing dual chambers (MED-P5D15A, from Panasonic, Tokyo, Japan) with DMEM-F12 media supplemented with 0.5 × B-27, 0.5 × N2 and 1% fetal bovine serum. Media was changed every 3-4 days. After 2 weeks, media was replaced with Neurobasal supplemented with 1 × B-27 and 1:400 Glutamax. Recording of spontaneous spike activity was done using the MED64 System (Panasonic). For Tetrodotoxin assays, functional cultures were submitted to Tetrodotoxin treatment (1 μM) and spontaneous activity was recorded before, during and 1 h after washout of Tetrodotoxin. For epigenetic compound treatment, neurons were treated every other day for 1 week with 10 μM of Scriptaid or NCH-51. Activity was measured in the following week. Only MEA channels with similar number and density of cells plated, and with more than 10 spikes in 5-min intervals were used in the analysis. Glutamatergic agonists (AP5 and NBQX) were used to check neuronal activity. After measurement, neurons were immunostained to check Technologies) . The next day (day 0), neural differentiation was induced by removing bFGF and adding 10 μM Rock inhibitor Y-27632 (Tocris). Two days later (day 2), media was changed to fresh media without Rock inhibitor. Media was changed every 3-4 days. After 3 weeks of differentiation, cells were treated in replicates (at least four wells per condition) with compounds of the Screen-Well Epigenetics library BML-2836 (Enzo Life Sciences, Farmingdale, NY, USA). It comprises 43 compounds carrying activity against lysine-modifying enzymes. A single dose of 10 μM was used in this screening for 1 week with complete media change every 2 days. On the final day of screening (day 28 of differentiation), cells were fixed with 100% methanol for 10 min, washed three times with PBS and blocked with blocking buffer for fluorescent western blotting (Rockland, Pottstown, PA, USA). After 4 h of blocking, PSD95 (NeuroMab) primary antibody was added at 1:250 dilution in blocking buffer. Cells were incubated 16 h at 4°C under light agitation. After wash (five times) with PBS-Tween 0.1%, cells were incubated with 800 IRDye-conjugated secondary antibodies (LiCor) at 1:800 dilution in blocking buffer with Tween-20 0.2% for 1 h at RT and moderate agitation. For normalization, DRAQ5 and Sapphire700 (LiCor) were added concomitantly with secondary antibody. After incubation, cells were washed (five times) with PBS-Tween-20 0.1% under moderate agitation. Plates were read on Odyssey CLx infrared imaging system (LiCor). PSD95 signal was normalized to cell content (DRAQ5 and Sapphire700) and results were plotted using the software GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Statistical analysis
At appropriate places, results were expressed as means ± s.e.m. Statistical analysis was performed by unpaired Student's t-test or one-way analysis of variance, where Po 0.05 was considered significant and Po 0.01 was considered as highly significant.
RESULTS
Genetic characterization of the MECP2 duplication locus
Duplication of the Xq28 chromosomal region, including MECP2, is a well-known chromosomal rearrangement that is characteristically non-recurrent in nature. Duplication sizes and gene content are highly variable among patients, but genotype-phenotype studies in humans and mice confirmed the increased dosage of MeCP2 as the underlying cause of the severe neurodevelopmental phenotypes. 1, 2, 16, 17, 24 In this study we included three male patients with different Xq28 duplication sizes, ranging from 300 Kb up to 15 Mb in size, all involving the MECP2 gene (Figure 1a) . Clinical history of the respective patients is described in the Methods section.
Increased MECP2 expression does not affect iPSC derivation MECP2dup and control male iPSC clones (see Supplementary  Table S1 ) were derived from fibroblasts using retroviral reprogramming vectors (Sox2, Oct4, c-Myc and Klf4) as previously described. 18 The different iPSC lines were validated by analyzing the endogenous expression of pluripotent genes at the transcript level and, secondly, by analyzing their potency to generate the three germ layers by EB in vitro differentiation and in vivo teratoma assays (Supplementary Figures S1a-e) . We confirmed by array-CGH that the Xq28 copy number variant, initially present in the patients' cell lines, remained stable during reprogramming (Supplementary Figure S1f) . IPSC lines that accumulated additional copy number variations during reprogramming were excluded from the study. Western blot analysis confirmed a two-fold overexpression of MeCP2 in all reprogrammed patients' cell lines, reflecting the double dosage of MECP2 (Supplementary Figure  S1g) . Overall, our data demonstrate that increased MeCP2 dosage does not interfere with the reprogramming process.
Patient and control iPSCs can be differentiated into neuronal cells of cortical identity As cortical dysfunction is observed in patients with MECP2 duplication syndrome, we chose to study the pathophysiological mechanism in iPSC-derived neurons with cortical identity. We used a differentiation protocol that involves an intrinsic mechanism for efficient generation of forebrain progenitors and pyramidal neurons from human iPSCs 20 (a schematic summary can be seen in the Supplementary Figure S1h) . Immunostaining confirmed the neuroectoderm progenitor identity of the cells obtained after 20-30 days of differentiation (Figure 1b) . Analysis of transcripts during the early course of differentiation (day 20-30) showed a difference in the expression of BLBP, a marker for neural progenitors, and FOXG1, a marker for telencephalic identity, with patient-derived NPCs expressing more than the control NPCs (Figure 1c and Supplementary Figure S1i To determine whether the derived iPSCs are able to generate functional neurons, we used the MEA electrophysiology technique. MEA electrophysiology is a non-invasive way to explore the network activity and connectivity status of neurons. 26 Using an in-house developed protocol to generate three-dimensional neurospheres (detailed in Materials and Methods and illustrated in Supplementary Figures S2c-f) , we successfully record and manipulate action potentials from our neuronal networks (Figure 2e ). Finally, we used a bicistronic lentiviral vector system co-expressing GFP and WGA for network tracing. 21, 22 Although WGA is a non-replicating tracer that undergoes dilution at each synaptic transfer, limiting its quantitative potential, this technique is useful in revealing the presence of physical contacts between iPSC-derived neurons (Figure 2f ). No significant difference in the number of WGA-positive neurons was found between MECP2dup and controls ( Supplementary Figures S2g and h ).
Increased glutamatergic synapse number and altered dendritic morphology in MECP2dup neurons Previous studies in mice showed that MECP2 dosage has a major impact on the formation of excitatory synapses. Decreased MeCP2 levels result in a lower number of glutamatergic synapses, whereas increased MeCP2 dosage leads to increased synaptic numbers. 27 However, more in-depth studies showed that the increased spine density due to increased MeCP2 protein dosage is mainly present in early neurogenesis and decreased with age.
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Human iPSC-derived neurons from RTT have a decreased number of glutamatergic synapses, 14 indicating a pivotal role of MeCP2 in the homeostasis of excitatory synapses. Gene expression profile of neurons derived from patients with MECP2 duplication syndrome revealed a trend toward a higher level of expression of the synaptic genes VGLUT1 and PSD95 (Figure 2a and Supplementary Figure S2a for individual clones) . Moreover, puncta quantification of co-localized pre-and post-synaptic markers confirmed an increased number of glutamatergic synapses in patient-derived neurons compared with controls ( Figure 3a and Supplementary A human MECP2 duplication model S Nageshappa et al Figure S3a for individual clones). To confirm the major influence of MeCP2 dosage in the observed phenotypes, we extended the puncta analysis in control and MECP2dup neurons in which the levels of MECP2 expression were modulated, either by overexpression (in control neurons) or by repression using shRNA (in MECP2dup neurons)( Supplementary Figures S3b and d) . In addition, western blot analysis confirmed the presence of higher Synapsin-1 and PSD95 protein levels in patient-derived neurons (Figure 3b and Supplementary Figures S3c and d) .
To study the effect of increased MeCP2 dosage on neuronal morphology, we investigated the dendritic arborization using Sholl analysis. Studies in mice models reported contrasting results, depending on the experimental design. 11, 28, 29 Our data indicate that human MECP2dup neurons have significantly increased dendritic arborization compared with control neurons (Figure 3c ). To study spine morphology and density, neurons were transduced with pHIV7/syn-EGFP and further differentiated until day 70, to enable correct morphological analysis. GFP-labeled dendrites were randomly selected and spines were analyzed manually for their morphology, as previously described. 23 As shown in Figure 3d , the total spine density per primary dendritic unit did not differ significantly between control and patient neurons. However, given the significant increased dendritic complexity, the absolute number of spines will be higher in the disease neurons. Interestingly, we observed more immature and less mature spines per dendritic length in the MECP2dup neurons. Alterations of dendritic spines or spine dysgenesis represent a common hallmark of intellectual disability and related synaptopathies. 30 A recent paper demonstrated the importance of Cux1 in regulating dendritic branching and spine density in upper layer neurons. 31 Western blotting confirmed an upregulation of Cux1 protein levels in our MECP2 duplication samples compared with controls, indicating that MeCP2 may in fact be regulating the levels of Cux1 in our cultures (Figure 3e Altered network phenotype of MECP2dup neurons Although most studies of the nervous system using iPSC rely on the premise that a synaptic phenotype in vitro could ultimately drive a network phenotype, few explored the real implications of these findings. To better explore this venue, we investigated whether the imbalance in glutamatergic synapses could drive a functional neuronal phenotype using MEA. Aligned roster plots of independent channels show that both MECP2dup and control neuronal cultures displayed neuronal synchronized activity, measured by overlapping spike burst from different channels (Figures 3g and h, and Supplementary Figures S3g and h) . Synchronized activity spreading through multiple electrodes indicates information flow in the neuronal network via synapse signaling. Interestingly, overlapping the spike activity histogram from different channels reveals a distinct frequency of synchronized activity for MECP2dup neuronal networks, with significantly more synchronized burst events compared with controls ( Figure 3g and Supplementary Figure S3h) . Again, we could confirm the central role of MeCP2 dosage on the functional phenotype, by repeating the MEA assays in control and MECP2dup neurons in which the levels of MECP2 expression were modulated, as described above (Figure 3i ).
Epigenetic modifiers screening in MECP2dup neurons
Given the multiple roles of MeCP2 at the epigenetic level, we decided to explore the possibility of rescuing the neuronal phenotypes using an epigenetic modifier library of compounds (Screen-Well Epigenetics library from Enzo, see Materials and Methods for a description and Supplementary Table S2 ). Using the InCell Western screening technology, we measured levels of PSD95 as a readout for our screening (Figure 4a ) and confirmed that this new tool is able to replicate the results from western blotting (Figure 3b ). This method of screening proves to be reliable and fast, avoiding the demanding human input required in the current state-of-the-art techniques. PSD95 was selected given its core importance in the formation of mature synapses. In addition, given its physical interactions with several other synaptic proteins found mutated in many neurodevelopmental syndromes such as autism (Supplementary Figure S4a) , a screening platform based on this phenotype can be useful to screen therapeutic compounds in these neurodevelopmental disorders as well.
Using a library of 43 compounds (schematic protocol in Supplementary Figure S4b) , we found five inhibitors that matched two criteria: (1) having a very significant P-value score (P o 0.001) and (2) reducing PSD95 protein levels close to control levels after 1 week of treatment (Figure 4b and Supplementary  Tables S2 and S3 ). Their mechanisms of action are scattered over distinct categories, for example, histone deacetylase (HDAC) inhibitors (Scriptaid, NCH-51 and NSC-3852), DNA (e) Puncta quantification of post-and pre-synaptic markers after treatment with epigenetic modifiers. The synaptic proteins Vglut1 (pre-synaptic) and PSD95 (post-synaptic) were used as markers and only co-localized puncta were quantified and graphed. Scale bar = 10 μm. One-way ANOVA test used to represent data after treatment using Dunnett's multiple comparison test and comparing with MECP2dup (*P o0.05). P-values per comparison: MECP2dup vs control = Po0.05; MECP2dup vs MECP2dup+NCH-51 = Po0.01; MECP2dup vs MECP2dup+Scriptaid = P o0.0001. Bars represent mean ± s.e.m. Three independent differentiation experiments. (f) Functional rescue after treatment with epigenetic modifiers; MEA was used to measure activity. Total spikes counts are shown before and after treatment with compounds. Unpaired t test used to compare control and MECP2dup data before treatment (*P = 0.0110). One-way ANOVA test used to represent data after treatment using Dunnett's multiple comparison test comparing with MECP2dup+Vehicle (**Po0.01 and ****P o0.0001). Bars represent mean ± s.e.m. Three independent differentiation experiments. MEA, multielectrode array. methyltransferase inhibitor (Zebularine) and histone methyltransferase inhibitor (BIX-01294). The HDAC inhibitors Scriptaid and NCH-51 were chosen to further access their potential in rescuing the other observed MECP2dup neuronal phenotypes.
First, we measured the impact of these two compounds in rescuing neuronal morphology (Figures 4c and d and  Supplementary Table S4 for statistics). Given that both inhibitors rescued the branching phenotype to control levels, we then quantified co-localized puncta number after treatment with the epigenetic modifiers (Figure 4e ). Once more, both compounds were able to rescue the glutamatergic imbalance present in the MECP2dup neurons. In addition, although these compounds seem to regulate glutamatergic synapse number in MECP2dup samples, they did not affect the control neurons ( Supplementary  Figures S4c and d) , suggesting a specific target pathway. Finally, MEA electrophysiology was used to assess whether we could also rescue the altered network phenotype (Figure 4f) . MECP2dup neurons presented a higher number of action potentials than the control cultures, which correlates with the higher level of synchronized burst activity (Figures 3g and h, and  Supplementary Figure S3i) . After treatment, MECP2dup neurons treated with NCH-51 showed reduced levels of activity, almost to the same level as seen in the controls (Figure 4f ). Interestingly, patient neurons treated with Scriptaid had their activity completely abolished.
DISCUSSION
To study human neurons with altered MECP2 gene dosage, we derived iPSC from fibroblasts isolated from three independent patients with MECP2 duplication syndrome. Although one of the patients carries a large duplication of 15 Mb, involving many other X-linked genes, the data obtained from different patients seem to be in coherence in most of the assays, including the MEA electrophysiology. Moreover, the central role of MeCP2 in neuronal connectivity and electrophysiology was further confirmed when its expression was modulated in control or disease neurons, respectively. These experimental data confirm the many clinical observations, indicating the dominant role of the increased MeCP2 dosage in the described phenotypes.
The increased MeCP2 expression did not interfere with the reprogramming and neuronal differentiation processes in our study. Cortical neurons derived from human MECP2dup iPSC lines showed an increased number of glutamatergic synapses when compared with non-affected controls and RTT-derived neurons. 14 We also found increased dendritic arborization and complexity in these neurons, again in sharp contrast to what we observed in RTT-derived neurons.
14 This is also in agreement with transgenic mouse data, confirming that MECP2 overexpression promotes early postnatal dendritic and synaptic growth. 7, 11 In addition, we observed altered spine morphology, a hallmark of many neurodevelopmental disorders, and it will be of interest to further investigate this observation in post-mortem brain samples.
30
MeCP2 was reported to modulate multiple pathways affecting dendritic plasticity. 12 From the myriad of genes that may be affected by MeCP2, we observed increased levels of CUX1, a gene previously identified as a dendritic branching modulator.
31 CUX1 controls the development of dendritic branching and promotes dendritic spine development and stabilization during early neuronal differentiation. In a Drosophila model, increasing levels of Cut, the fly homolog, resulted in increased branching and elevated dendritic spike numbers. 32 We speculate that CUX1 expression can be upregulated by direct binding of MeCP2, which might constitute a potential mechanism for some of the observed MECP2 duplication syndrome pathophysiology in our human in vitro model.
Electrophysiological analysis using MEA showed that MECP2dup neurons have a significant increased frequency of activity and synchronized bursts compared with controls. In combination with the increased glutamatergic synaptic puncta number observed, it suggests the presence of more active synapses on these neurons, which allows this fast pace flow of information through the network. A similar observation was seen in two different transgenic mouse models, where overexpression resulted in enhanced synaptic plasticity, at least in young animals. 7, 8 Our study in human neurons illustrates the importance of correct MECP2 dosage for synaptic plasticity and homeostasis during brain development and function. Failure of homeostasis, either by haploinsufficiency or overexpression will result in neurodevelopmental phenotypes. 12 To our knowledge, this is the first time that synchronized burst events from iPSC-derived human neuronal networks are recorded on MEA, without using co-culture with astrocytes. [33] [34] [35] Our analysis show a clear correlation between synapse number and functional synchronized activity in human iPSC-derived neurons, revealing the potential of MEA to the study of neurodevelopmental disorders that involve synaptic deficits.
In an attempt to identify compounds that could rescue the effects of increased MeCP2 dosage, we adapted the technology of InCell Western to measure the levels of PSD95 protein in our cultures. This synaptic protein was chosen given its core function in synaptic formation and the synaptic imbalance found in MECP2dup cultures. Using an epigenetic chemical library, we encountered two HDAC inhibitors that were able to reduce PSD95 protein to control levels but did not affect control neurons. Treatment of MECP2dup neurons with these two HDAC inhibitors (Scriptaid or NCH-51) for a week was sufficient to rescue several aspects of neuronal morphology. It is known that MeCP2 exerts its gene-silencing ability through chromatin modification mediated by its interaction with Sin3A/HDACI or Ski/NcoR/HDACII repression complexes, 36 pointing to this pathway as a potential therapeutic avenue for this syndrome. However, our data also suggest caution on the quest for therapeutic compounds. Although both HDAC inhibitors seem to rescue the aberrant morphology, only NCH-51 is able to correctly ameliorate the functional phenotype. Ultimately, this demonstrates the power and necessity of accessing several cellular and functional rescues before in vivo tests. This strategy could reduce downstream failures and expenses in the quest for therapeutic compounds.
Our data indicate that human iPSCs not only can recapitulate some aspects of a genetic neurodevelopmental disorder caused by a genomic duplication, but can also be used in assays to screen potential drugs for the ability to rescue neuronal phenotypes. This cellular model and the novel techniques developed here may help investigators to better design and anticipate results from translational medicine studies, with the potential to lead to the discovery of new compounds to treat neurodevelopmental disorders.
